ID
17743
Description
NCT00334568/ GSK-AVA100193: M.Alzheimer GSK A 24 week double-blind, randomized, placebo-controlled, parallel-group dose-raging study to investigate the effects of rosiglitazone (extended release tablets) on cognition in subjects with mild to moderate Alzheimer´s disease. Medicine: rosiglitazone, Condition: Alzheimer´s Disease, Phase: 2, Clinical Study ID: AVA 100193, Sponsor: GSK. This ODM contains Book 3/Visit 3.
Keywords
Versions (3)
- 9/14/16 9/14/16 -
- 10/2/16 10/2/16 -
- 12/14/16 12/14/16 -
Uploaded on
October 2, 2016
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
NCT00334568/ GSK-AVA100193: M.Alzheimer GSK - Book 3
NCT00334568/ GSK-AVA100193: M.Alzheimer GSK - Book 3
- StudyEvent: ODM
Description
Vital Signs
Description
Weight
Data type
float
Measurement units
- kg
Description
Blood pressure and heart rate will be measured once, after the subject sits quietly for at least 5 minutes.
Data type
integer
Description
Blood pressure
Data type
integer
Measurement units
- mmHg
Description
Heart Rate
Data type
integer
Measurement units
- bpm
Description
Concomitant Medications
Description
Adverse Events
Description
Physical Examination
Description
Pedal Oedema
Description
End of visit reminder
Similar models
NCT00334568/ GSK-AVA100193: M.Alzheimer GSK - Book 3
- StudyEvent: ODM